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Abstract 
The β-OG pocket is a cavity in the flavivirus envelope (E) protein that was identified by Modis et al. 
(2003) as a promising site for the design of antiviral agents that interfere with virus entry into the 
host cell. The availability of the X-ray crystal structure of the dengue virus (DENV) E protein provided 
an opportunity for in silico drug design efforts to identify candidate inhibitors. The present study was 
set up to explore whether it is possible to generate a novel class of molecules that are hybrids 
between two hit compounds that have been reported previously by Zhou et al. (2008) following an in 
silico screening effort against the DENV E protein. First, a library of twenty hybrid molecules were 
designed and synthesized to explore the feasibility of this strategy. Antiviral evaluation in a virus-cell-
based assay for DENV proved this approach to be successful, after which another twenty-four 
molecules were produced to further explore and optimize the potency of this novel class of hybrid 
inhibitors. In the end, a molecule was obtained with an EC50 against dengue virus serotype 2 in the 
low micromolar range (23, 1.32 ± 0.41 µM). 
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Dengue fever is a mosquito-transmitted viral disease that in the past decades has become endemic in 
most, if not all, tropical and sub-tropical regions around the world. Yearly, an estimated 50 to 200 
million infections are caused by dengue virus (DENV),1 with a fatal outcome in over 2.5% of the 
cases.2 Globalization and climate change are drivers that continue to increase the impact of this 
infectious disease on human health.3 The pharmaceutical industry is heavily investing in the 
development of an efficient vaccine, which until now still has failed to fulfill its promise.4 Several 
antiviral drugs for the treatment or prevention of DENV infections are in the (pre)clinical stage, but it 
will take several more years before the first one will reach the clinic._ENREF_5 In this latter context, 
any stage in the viral replication cycle may represent a possible target for the development of such 
small-molecule inhibitors.5-7 
In 2003, Modis and colleagues reported the crystal structure of the DENV envelope (E) protein 
(1OKE).8 In this structure, a density was observed that could be attributed to an n-octyl-β-D-glucoside 
(β-OG) molecule, a detergent that is commonly used for the production of protein crystals. The cavity 
in the E protein in which this molecule fits, also designated the β-OG pocket, quickly drew the 
attention for structure-based drug screening and design efforts, especially because it was shown that 
fusion of the virus envelope with host cell membranes requires a pronounced conformational change 
of the E-protein as well as this cavity.9, 10 In this context, it was put forward that freezing the E protein 
in its pre-fusion state by filling the β-OG pocket with a small molecule would prevent virus fusion and 
thus would offer a novel and promising strategy for the development of a drug for the treatment or 
prevention of DENV infections. 
In 2008, Zhou and colleagues performed a large-scale in silico screen from which the 23 top-ranking 
compounds were selected for evaluation in a yellow fever virus (YFV) assay as alternative for DENV.11 
Several compounds showed inhibitory activity, by which they validated this novel drug discovery 
approach. The purpose of the present study is to explore whether a novel hybrid chemical scaffold 
with more potent antiviral activity against DENV can be developed based on compounds M02 and 
D03 that have been reported in the aforementioned study (Figure 1). Even though these compounds 
were shown to only have inhibitory activity in the higher micromolar range in the YFV assay (M02: 
IC50= 51±7 µM & D03: IC50=31±0.3 µM, respectively), because YFV and DENV have a ~43.8% 
sequence identity at the amino acid level of the E protein (and even higher for the amino acids that 
line the β-OG pocket),12 it was envisaged that compounds with similar or even a more potent 
inhibitory effect against DENV could be obtained. A similar approach was reported by Li et al. 
(2008),13 which yielded methyl-4-(dibromomethyl)-2-(4-chlorophenyl)thiazole-5-carboxylate, a 
compound that later was developed into a metabolically more stable analogue by Mayhoub et al. 
(2011).14 Few more reports on the identification of fusion inhibitors through High-Throughput Virtual 
Screening (HTVS) are available.12, 15-17_ENREF_10  
So far, all inhibitors of DENV infection that target the β-OG pocket have not been further developed. 
However, novel compound series undoubtedly will contribute to a better understanding of this 
pocket as target for small-molecule inhibitors. 
A first series of twenty compounds (1-20, Table 1) was designed as hybrid molecules by grafting half 
of the structure of compound M02 onto half of the structure of compound D03 (see Zhou et al., 
2008) (Figure 1). The resulting pyrazoline derivatives (1-20) were synthesized through the reactions 
outlined in Scheme 1A.18 The synthesis starts with the preparation of chalcones from appropriate 
benzaldehydes and acetophenones in the presence of sodium hydroxide (60%) using methanol as 
solvent at room temperature for a period of 48 h. The resulting chalcones were converted into the 
respective pyrazolines by the reaction of thiosemicarbazide in the presence of sodium hydroxide 
under reflux using methanol as solvent for a period of 8-10 h. The final compounds (1-20) are 
obtained by the reaction of appropriate pyrazolines with either p-chloro phenacyl bromide or p-
phenyl phenacyl bromide under reflux using ethanol as solvent for a period of 30-45 min.  
None of the twenty molecules were able to inhibit the development of virus-induced cytopathic 
effects (CPE, virus-induced cell death) when compound and virus were added to the cells at the same 
time. However, when virus and compound were mixed and pre-incubated for 2 h at 37 °C, four 
compounds (9, 13, 19, 20) showed antiviral activity. Based on only these four active compounds in 
the library of pyrazolines (1-20), it was not feasible to deduct a detailed structure-activity 
relationship. However, useful information could be derived to devise further strategies for lead 
optimization. For example, the substitutions 4-biphenyl thiazol-2-yl, 4-methoxyphenyl and 3-
methoxy-4-hydoxyphenyl at N1, 3rd and 5th position of the pyrazoline, respectively, appear to be 
favorable for antiviral activity. Compound 19 (EC50: 3.79 ± 1.22 µM, Table 3) was found to be the 
most potent amongst the twenty compounds.  
Encouraged by and based on the results that were obtained with compounds 1-20, compounds 21-44 
(Table 1) were designed as open ring analogues of the hybrid scaffold with 7C-minus (phenyl ring at 
5th position of pyrazoline and C5 of pyrazoline; 21-25, 33-38) and 8C-minus (phenyl ring at 5th 
position of pyrazoline and C4-C5 of pyrazoline; 26-32, 39-44) (Figure 1). This is consistent with the 
observation made by Li et al.: through simulation studies, they proposed that 5-aryl substitutions on 
the pyrazole moiety prevented the chlorophenyl thiazole part of the molecule to be completely 
embedded in the hydrophobic pocket.13 All hydrazones were synthesized through reactions outlined 
in Scheme 1B.18-20 The synthesis starts with the preparation of thiosemicarbazones of appropriate 
benzaldehyde and acetophenones in the presence of catalytic amount of glacial acetic acid using 
methanol as solvent. The reaction was carried out in room temperature for about 2 h. The final 
compounds (21-44) were prepared through the reaction of thiosemicarbazones with appropriate 
phenacyl bromide (p-chloro phenacyl bromide, p-phenyl phenacyl bromide) in methanol under room 
temperature, with stirring for about 30-60 minutes.  
From the collection of thiazolyl hydrazones (21-44), five compounds (23, 36, 37, 39, 41) were shown 
to elicit a antiviral effect in the DENV assay in which the compounds were pre-incubated with the 
virus. These results indicate that the benzaldehyde hydrazones of 4-biphenyl thiazole-2-hydrazides 
(39, 41) and acetophenone hydrazone of 4-chlorophenyl thiazole-2-hydrazide (23) are essential for 
antiviral activity. From this series, in particular compound 23 markedly inhibited DENV-induced cell 
death with the best selectivity index of all compounds (EC50: 5.8 ± 1 µM; CC50: 145.2 ± 12; SI: 25, 
Table 2, Figure 2). Due to the stringency of the virus-cell-based screening assay, only compounds that 
have a clear antiviral effect produce an EC50 value, which explains that only few were found to have a 
cell protective effect.  
For each of the nine compounds that showed activity in the CPE reduction assay, the antiviral activity 
was validated by quantification of the dose-response effect on the amount of dengue virus RNA that 
is produced by virus-infected, compound-treated cells (Table 3). For all nine compounds, an 
inhibitory effect was also observed in this assay, which for most of the compounds was 
proportionate to the previously observed cell protective effect. The antiviral activity of the most 
potent compound, i.e. compound 23, was further validated by quantification of the dose-response 
effect on the production of infectious dengue virus progeny. Compound 23 exhibited a pronounced 
dose-dependent inhibition of plaque formation (EC50 = 1.39 ± 0.06 µM, Figure 3), which was similar 
to the inhibition of viral RNA synthesis as determined in the virus yield reduction assay (EC50 = 1.32 ± 
0.41 µM, Table 3). Based on its antiviral potency and selectivity in both assays, compound 23 will 
become the subject of a more detailed and elaborate virological study into its precise molecular 
mechanism of action. 
Analysis of the compounds docked into the β-OG pocket shows similar binding modes for compounds 
1-10, for which the 4-chlorophenyl thiazolyl portion was found to partially occupy the hydrophobic 
pocket or to be placed at the surface. For compound 11-20, the biphenyl thiazolyl portion is well 
accommodated in the hydrophobic pocket, and three compounds (13, 19, 20) were found to be 
active. In case of compounds 21-44, the 4-chlorophenyl thiazolyl and biphenyl thiazolyl portions were 
accommodated in variable positions into the hydrophobic pocket, which is predominantly 
determined by the nature and substitution(s) on the head group (pyrazoline and hydrazone portion).  
Figure 4A shows the interaction of compound 23 within the E protein of DENV. Van der Waals 
interactions predominate and there is an H-bonding interaction between the side chain carbonyl 
oxygen of THR280 and the hydrogen of thiazole N-H of compound 23. The side chain methyl group of 
compound 23 engages into a strong hydrophobic interaction with the side chain of ILE270 and 
LEU277. The 4-chlorophenyl ring at the 4th position of the thiazole engages into a π-π staking 
interaction with PHE193 and PHE279, and hydrophobic interaction with LEU207. The 3,4-
dichlorophenyl portion of MO2 and 4-chlorophenyl portion of DO3 were reported to exhibit a strong 
hydrophobic interaction with LEU207, but no π-π staking was reported.11 It is this interaction that 
causes compound 23 to rank as the most potent amongst the nine actives. Compound 29 lacks the 
side chain methyl group that overlaps with compound 23 at the 4-chlorophenyl thiazole portion. 
Furthermore, due to a slight deviation of the head group (which is positioned near the surface), the 
hydrophobic interaction with either ILE270 or LEU277 cannot be established. While compound 3 can 
be seen as a cyclic precursor, it cannot insert its 4-chlorophenyl thiazole portion into the hydrophobic 
pocket (Figure 4A, 2D-plots are provided in the Supplementary material). Analysis of compound 13, 
35 and 41 showed that only compound 41 could position its biphenyl portion in such a way that it 
establishes the favorable π-π staking with PHE193 and PHE279. This explains why this molecule is 
more potent than its cyclic counterpart 13. Compound 35, which differs from 41 only by one methyl 
group, incompletely occupies the hydrophobic pocket while the head portion is largely exposed to 
the solvent. This explains the inactivity of this molecule (Figure 4B, 2D-plots are provided in 
Supplementary material). As to what concerns compounds 19, 36 and 42; compound 19 establishes 
hydrophobic interactions and π-π stacking in the hydrophobic pocket as well as H-bonding 
interaction (GLN200, LYS202) and π-cation interaction (LYS47) near the surface. This renders this 
compound more potent than compound 36, its open ring counterpart. Compound 42, which differs 
from compound 36 by one methyl group, can be freely accommodated by the cavity but is not able 
to establish a π-π interaction with either PHE193 or PHE297 (Figure 4C, 2D-plot are provided in 
Supplementary material). In summary, the following interactions at the hydrophobic pocket are 
essential for antiviral activity: (i) the π-π interaction with either PHE193 or PHE297, (ii) hydrophobic 
interaction with LEU207, and (iii) interactions at the surface by (a) a hydrophobic interaction with 
either ILE270 or LEU277 and (b) H-bonding interaction. The best molecule should establish H-bonding 
interaction near the surface, which helps in anchoring the molecule at the entrance (surface), 
thereby facilitating the tail portion (4-chlorophenyl or biphenyl portion) to be accommodated in the 
hydrophobic pocket, while establishing the π-π interaction. 
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Note: Refer Supplementary material for synthetic procedures, spectral characterization and 
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Table 1. Structural formulas of compounds 1-44 
 
 
 
 
 
 
 
      1-20                     21-44 
Code X R R
1
 R
2
 R
3
 Code X R R
1
 R
2
 R
3
 
1 CH -H -H -H -Cl 23 CH -CH3 -OH -Cl - 
2 CH -Cl -H -H -Cl 24 CH -CH3 -OCH3 -Cl - 
3 CH -OH -H -H -Cl 25 CH -CH3 -NO2 -Cl - 
4 CH -OCH3 -H -H -Cl 26 N -CH3 -H -Cl - 
5 CH -NO2 -H -H -Cl 27 CH -H -H -Cl - 
6 N -H -H -H -Cl 28 CH -H -Cl -Cl - 
7 CH -Cl -OH -OCH3 -Cl 29 CH -H -OH -Cl - 
8 CH -Cl -OH -H -Cl 30 CH -H -OCH3 -Cl - 
9 CH - OCH3 -OH -OCH3 -Cl 31 CH -H -NO2 -Cl - 
10 CH - OCH3 -OH -H -Cl 32 N -H -H -Cl - 
11 CH -H -H -H -C6H5 33 CH -CH3 -H -C6H5 - 
12 CH -Cl -H -H -C6H5 34 CH -CH3 -Cl -C6H5 - 
13 CH -OH -H -H -C6H5 35 CH -CH3 -OH -C6H5 - 
14 CH -OCH3 -H -H -C6H5 36 CH -CH3 -OCH3 -C6H5 - 
15 CH -NO2 -H -H -C6H5 37 CH -CH3 -NO2  -C6H5 - 
16 N -H -H -H -C6H5 38 N -CH3 -H -C6H5 - 
17 CH -Cl -OH -OCH3 -C6H5 39 CH -H -H -C6H5 - 
18 CH -Cl -OH -H -C6H5 40 CH -H -Cl -C6H5 - 
19 CH - OCH3 -OH -OCH3 -C6H5 41 CH -H -OH -C6H5 - 
20 CH - OCH3 -OH -H -C6H5 42 CH -H -OCH3 -C6H5 - 
21 CH -CH3 -H -Cl - 43 CH -H -NO2 -C6H5 - 
22 CH -CH3 -Cl -Cl - 44 N -H -H -C6H5 - 
 
 
 
  
Table(s)
Table 2. Antiviral activity against DENV-2 as determined in a CPE-reduction assay 
Compound EC50 (µM) CC50 (µM) SI 
9 0.79 2.4 3 
13 13.2 79.2 6 
19 8.4 ± 2.5 16.8 ± 4.1 2 
20 24.8 > 99 > 4 
23 5.8 ± 1.2 145 ± 12 25 
36 100 ± 9 200 ± 11 2 
37 41 ± 5 82 ± 7 2 
39 35.2 > 141 > 4 
41 16.8 > 135 > 8 
 
Values expressed in µM. Compound and virus was pre-incubated for 2 hours. For all other 
compounds, no antiviral activity has been observed (data not shown). 
 
Table 3. Antiviral activity against DENV-2 as determined in a virus yield reduction assay 
Compound EC50 (µM) CC50 (µM) SI 
9 7.00 ± 4.16 54.6 ± 38.8 8 
13 8.44 ± 2.02 86.8 ± 30.1 10 
19 3.79 ± 1.22 25.6 ± 11.9 7 
20 18.6 ± 5.50 99.3 ± 0.00 5 
23 1.32 ± 0.41 125.0 ± 40.8 95 
36 17.7 ± 4.50 116.8 ± 8.22 7 
37 12.2 ± 1.14 70.8 ± 43.2 6 
39 127.8 ± 29.9 > 141 > 1 
41 5.29 ± 4.80 > 135 > 25 
Ribavirin 47.9 ± 4.63 > 410 > 9 
 
Values expressed in µM. Values represents averages of 3 independent experiments. For all other 
compounds, no such data were generated. 
 
Legends to scheme and figures 
 
Scheme 1 Reagents and conditions A: (a) MeOH, NaOH (60%), rt, 48 h; (b) NH2-CS-NH-NH2, MeOH, 
NaOH, reflux, 8-10 h; (c) R3-C6H4-CO-CH2Br, EtOH, reflux, 30-45 min. B: (a) MeOH, NH2-CS-NH-NH2, 
(AcOH glacial), rt, 2 h; (b) MeOH, R2-C6H4-CO-CH2Br, rt, 30-60 min stirring. 
Figure 1 Design of Library molecules (1-44). 
Figure 2. CPE reduction assay of compound 23 (Pre-incubation antiviral assay)  
Figure 3. Dose-response effect of compound 23 on dengue virus serotype 2 plaque formation. The 
numbers of plaques were quantified on day 6 post-infection after fixation and staining 
Figure 4A. Compounds 3 (Green), 23(Blue), and 29 (Red) in BOG-pocket of DENV2 E-protein (PDB 
Code: 1OKE);   4B. Compounds 13 (Green), 35 (Blue) and 41 (Red) in BOG-pocket of DENV2 E-protein 
(PDB Code: 1OKE); 4C.  Compounds 19 (Green), 36 (Blue) and 42 (Red) in BOG-pocket of DENV2 E-
protein (PDB Code: 1OKE).  
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